Nutrition and Obesity Strategies for Primary Care
CME Credits:
5.75
MOC Credits:
5.75

Online

Nutrition and Obesity Strategies for Primary Care

Do you want to incorporate obesity medicine into your medical practice but don't know where to start? AACE’s course, Nutrition and Obesity Strategies for Primary Care is created for primary care physicians, physician assistants, nurse practitioners, and diabetes educators to equip and empower them with the necessary knowledge and skills to develop individualized approaches to help patients with metabolic disease, and other weight-related complications. Top endocrine experts will provide current evidence-based research and strategies to implement practical tools in your practice today.

Take your Nutrition and Obesity knowledge to the next level! This collection of lectures features the most recent and relevant topics in the field of Endocrinology. This online course contains video lectures, assessment questions, and the opportunity for CME and MOC!

 

5.75
CME/MOC Credits
4
Faculty
5
Lectures

Starts 7/21/2022 | Expires 7/21/2023

Lectures Included

  • Disease State Network Year-in-Review: Nutrition and Obesity - Monica Agarwal, MD, MEHP, FACE; Reshmi Srinath, MD
  • Precision Nutrition: Are We There Yet? - Zhaoping Li, MD, PhD
  • Diabetes Diets: A Roundtable Discussion
  • One Size Doesn’t Fit All: Pharmacotherapy, Endoscopic Devices and Metabolic Surgery for the Management of Obesity
  • A Blind Spot: Weight Bias and Health Disparities in Obesity Care - Scott Kahan, MD, MPH, FTOS

Learning Objectives

Upon completion of the activity, participants should be able to:

  • Assess recent research and clinical trials of dietary patterns, lifestyle interventions, bariatric/metabolic surgery and weight management medications
  • Develop an integrative individualized approach to help our patients with metabolic disease
  • Summarize the safety and efficacy of intermittent fasting diets, including time-restricted feeding, in the management of T2DM
  • Identify the magnitude and importance of weight bias in healthcare settings and several strategies for mitigating weight bias in clinical practice.
  • Review the impact of endoscopic manipulation of the gastrointestinal tract on appetite and estimate expected weight loss outcomes of currently available drugs and those on the horizon
Faculty

Faculty

Monica Agarwal, MD, MEHP, FACE

Reshmi Srinath, MD

Zhaoping Li, MD, PhD

Scott Kahan, MD, MPH, FTOS

Accreditation

Target Audience

This educational initiative is intended for the primary care team.

Accreditation Statement

The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American College of Endocrinology designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Disclosures/Conflicts of Interest

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

FirstMILastCredentialsPositionInstitutionRoleDisclosure(s)
SamanthaR.HarrisMDEndocrinologistScripps Clinic Medical Group, Center for Weight ManagementModeratorEli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
ScottD.IsaacsMD, FACP, FACEAdjunct Assistant Professor of MedicineEmory University School of MedicineSpeakerMadrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Medpace (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21); Quest (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 4/30/21)
Kenneth CusiMD, FACP, FACEChief of the Division of EndocrinologyUFLSpeakerAllergan Pharmaceuticals (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); AstraZeneca (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Axcellla (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); BMS (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Boehringer Ingelheim (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Cirius (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Coherus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Deuterex (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Echosens (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Eli Lilly (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Fractyl (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genentech (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Genfit (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); High Tide (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2021); Inventiva (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Janssen (Self) : Research Grant (Status: Terminated --- 2020); Madrigal (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Merck (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); National Institutes of Health (Self) : Grant/Research Support (Status: Ongoing), Research Grant (Status: Ongoing); Nordic (Self) : Research Support (Status: Ongoing); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing); Poxel (Self) : Research Grant (Status: Terminated --- 2021); Prosciento (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Sanofi-Adventis (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Viscera Labs (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 2020); Zydus (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Research Grant (Status: Ongoing)
MartinM.GrajowerMD, FACP, FACEClinical Professor of MedicineAlbert Einstein College of MedicineSpeakerAbbott/AbbVie (Self) : Honorarium (Status: Terminated --- 10/01/2021); Bayer (Self) : Honorarium (Status: Ongoing); echosense (Self) : Honorarium (Status: Ongoing); Novo Nordisk (Self) : Honorarium (Status: Ongoing)
Amy FischlMS, RDN, LDN, BC-ADM, CDCES University of ChicagoSpeakerAbbott Diabetes Care (Self) : Honorarium (Status: Ongoing); Xeris Pharmaceuticals (Self) : Honorarium (Status: Ongoing)

 

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The American Association of Clinical presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The American Association of Clinical Endocrinology assumes no liability for the information herein.